Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ community.

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.

The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.

The FDA approved the first oral treatments for paraganglioma, pheochromocytoma, and anal cancer in May.

Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's performance in actual clinical practice even exceeded the promising results from the clinical trial.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free and overall survival.

Adding durvalumab to perioperative FLOT upped event-free survival in patients with gastric or gastroesophageal adenocarcinoma eligible for resection.

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.